A detailed history of Royal Bank Of Canada transactions in Axogen, Inc. stock. As of the latest transaction made, Royal Bank Of Canada holds 35,245 shares of AXGN stock, worth $510,347. This represents 0.0% of its overall portfolio holdings.

Number of Shares
35,245
Previous 28,602 23.23%
Holding current value
$510,347
Previous $207,000 138.65%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$7.52 - $14.69 $49,955 - $97,585
6,643 Added 23.23%
35,245 $494,000
Q2 2024

Aug 14, 2024

SELL
$5.67 - $8.06 $2,954 - $4,199
-521 Reduced 1.79%
28,602 $207,000
Q1 2024

Nov 05, 2024

BUY
$6.63 - $10.69 $3,454 - $5,569
521 Added 1.82%
29,123 $235,000
Q1 2024

May 15, 2024

SELL
$6.63 - $10.69 $101,816 - $164,166
-15,357 Reduced 34.53%
29,123 $235,000
Q4 2023

Feb 14, 2024

BUY
$3.61 - $7.76 $32,576 - $70,026
9,024 Added 25.45%
44,480 $303,000
Q3 2023

Nov 14, 2023

BUY
$4.68 - $9.26 $123,842 - $245,038
26,462 Added 294.22%
35,456 $177,000
Q2 2023

Aug 14, 2023

BUY
$8.5 - $10.38 $4,666 - $5,698
549 Added 6.5%
8,994 $82,000
Q1 2023

May 15, 2023

SELL
$7.53 - $10.95 $31,919 - $46,417
-4,239 Reduced 33.42%
8,445 $79,000
Q4 2022

Feb 14, 2023

BUY
$9.44 - $13.09 $61,879 - $85,804
6,555 Added 106.95%
12,684 $126,000
Q3 2022

Nov 14, 2022

BUY
$8.14 - $12.25 $42,865 - $64,508
5,266 Added 610.2%
6,129 $74,000
Q2 2022

Aug 15, 2022

SELL
$6.99 - $10.0 $15,014 - $21,480
-2,148 Reduced 71.34%
863 $7,000
Q1 2022

May 16, 2022

SELL
$7.26 - $10.7 $50,682 - $74,696
-6,981 Reduced 69.87%
3,011 $24,000
Q4 2021

Feb 14, 2022

SELL
$8.8 - $16.0 $10,612 - $19,296
-1,206 Reduced 10.77%
9,992 $94,000
Q3 2021

Nov 15, 2021

BUY
$15.23 - $21.72 $23,393 - $33,361
1,536 Added 15.9%
11,198 $176,000
Q2 2021

Aug 16, 2021

BUY
$17.8 - $23.5 $171,983 - $227,057
9,662 New
9,662 $208,000

Others Institutions Holding AXGN

About Axogen, Inc.


  • Ticker AXGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 42,283,700
  • Market Cap $612M
  • Description
  • AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgic...
More about AXGN
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.